SCHEMBL25598596

SCHEMBL25598596

O=C(N[C@H](C(=O)O)C12CC3(Cl)CC(Cl)(CC(Cl)(C3)C1)C2)c1ccc2ccccc2c1OCc1ccc(SC(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CXCR2 P25025 6/20 0.46
▸ PTPRZ1 P23471 2/20 0.33
▸ KCNK2 O95069 1/20 0.33
▸ KCNK10 P57789 1/20 0.33
▸ PTPN2 P17706 1/20 0.33
▸ PTPN1 P18031 1/20 0.33
▸ PTPN7 P35236 1/20 0.33
▸ ALDH1A1 P00352 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ CAPN1 P07384 1/20 0.31
▸ NPC1 O15118 1/20 0.31
▸ RAB9A P51151 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ PDE2A O00408 1/20 0.31
▸ CHRM4 P08173 1/20 0.31
▸ KIFC1 Q9BW19 1/20 0.31
▸ NAMPT P43490 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25602752 1.00 CXCR2 (0.46) CXCR2PTPRZ1KCNK2KCNK10PTPN2
SCHEMBL25599446 0.92 CXCR2 (0.43) CXCR2PTPRZ1KCNK2KCNK10PTPN2
SCHEMBL25598661 0.92 CXCR2 (0.43) CXCR2PTPRZ1KCNK2KCNK10PTPN2
SCHEMBL23459942 0.92 CXCR2 (0.43) CXCR2PTPRZ1KCNK2KCNK10PTPN2
SCHEMBL23460939 0.91 CXCR2 (0.46) CXCR2PTPRZ1KCNK2KCNK10PTPN2
SCHEMBL23460936 0.91 CXCR2 (0.46) CXCR2PTPRZ1KCNK2KCNK10PTPN2
SCHEMBL25601090 0.90 CXCR2 (0.41) CXCR2PTPN2PTPN1PTPN7
SCHEMBL25598610 0.90 CXCR2 (0.42) CXCR2PTPRZ1KCNK2KCNK10PTPN2
SCHEMBL25599187 0.90 CXCR2 (0.42) CXCR2PTPRZ1KCNK2KCNK10PTPN2
SCHEMBL23460088 0.87 CXCR2 (0.46) CXCR2PTPRZ1KCNK2KCNK10ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF GENZYME CORPORATION 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159439-A1 ARYLAMIDES AND METHODS OF USE THEREOF CFTR, AADAC, ARSA CXCR2 1205/4885PTPRZ1 1172/4885KCNK2 1269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback